Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.

Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S, Sundar HM, Trent JC, Wayne JD.

J Natl Compr Canc Netw. 2010 Apr;8 Suppl 2:S1-41; quiz S42-4.

2.

NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CD, Gronchi A, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, von Mehren M, Wayne JD, Zalcberg J; NCCN Task Force.

J Natl Compr Canc Netw. 2007 Jul;5 Suppl 2:S1-29; quiz S30. Review. Erratum in: J Natl Compr Canc Netw. 2007 Aug;5(7):xxx.

PMID:
17624289
3.

A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST.

Blay JY.

Cancer Treat Rev. 2011 Aug;37(5):373-84. doi: 10.1016/j.ctrv.2010.11.003. Epub 2010 Dec 30. Review.

PMID:
21195552
4.

[Resistance against tyrosine kinase inhibitors in the treatment of GIST. New therapeutic possibilities appear].

Ahlman H, Nilsson O, Nilsson B.

Lakartidningen. 2009 Dec 9-21;106(50-51):3424-9. Review. Swedish. No abstract available.

PMID:
20180446
5.

Primary gastrointestinal stromal tumor of the liver treated with sequential therapy.

Lin XK, Zhang Q, Yang WL, Shou CH, Liu XS, Sun JY, Yu JR.

World J Gastroenterol. 2015 Feb 28;21(8):2573-6. doi: 10.3748/wjg.v21.i8.2573.

6.

NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines.

Demetri GD, Benjamin R, Blanke CD, Choi H, Corless C, DeMatteo RP, Eisenberg BL, Fletcher CD, Maki RG, Rubin BP, Van den Abbeele AD, von Mehren M; NCCN GIST Task Force.

J Natl Compr Canc Netw. 2004 May;2 Suppl 1:S-1-26; quiz 27-30.

PMID:
23573667
7.

Management of gastrointestinal stromal tumors.

Hueman MT, Schulick RD.

Surg Clin North Am. 2008 Jun;88(3):599-614, vii. doi: 10.1016/j.suc.2008.03.001. Review.

PMID:
18514701
8.

Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations.

Blay JY, Reichardt P.

Expert Rev Anticancer Ther. 2009 Jun;9(6):831-8. doi: 10.1586/era.09.34. Review.

PMID:
19496720
9.

Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors.

Li J, Gao J, Hong J, Shen L.

Future Oncol. 2012 May;8(5):617-24. doi: 10.2217/fon.12.29.

PMID:
22646775
10.

Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.

Yoon DH, Ryu MH, Ryoo BY, Beck M, Choi DR, Cho Y, Lee JL, Chang HM, Kim TW, Kang YK.

Invest New Drugs. 2012 Apr;30(2):819-27. doi: 10.1007/s10637-010-9593-1. Epub 2010 Nov 23.

PMID:
21104107
11.

[Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].

Nishida T, Omori T, Ueshima S.

Gan To Kagaku Ryoho. 2011 May;38(5):733-7. Japanese.

PMID:
21566432
12.

Developments in targeted therapy of advanced gastrointestinal stromal tumors.

Rutkowski P, Symonides M, Zdzienicki M, Siedlecki JA.

Recent Pat Anticancer Drug Discov. 2008 Jun;3(2):88-99. Review.

PMID:
18537751
13.

Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options.

Caram MV, Schuetze SM.

J Surg Oncol. 2011 Dec;104(8):888-95. doi: 10.1002/jso.21930. Review.

PMID:
22069173
14.

Current management of gastrointestinal stromal tumors--a comprehensive review.

Lai EC, Lau SH, Lau WY.

Int J Surg. 2012;10(7):334-40. doi: 10.1016/j.ijsu.2012.05.007. Epub 2012 May 24. Review.

15.

Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.

Blanke CD, Huse DM.

J Med Econ. 2010;13(4):681-90. doi: 10.3111/13696998.2010.534670. Epub 2010 Nov 10. Review.

PMID:
21067355
17.

[Sunitinib as a second-line therapy for imatinib-resistant gastrointestinal stromal tumors].

Ishikawa T, Kanda T, Kosugi S, Yajima K, Hatakeyama K.

Gan To Kagaku Ryoho. 2011 Jun;38(6):916-21. Japanese.

PMID:
21677482
18.

Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.

George S, Reichardt P, Lechner T, Li S, Cohen DP, Demetri GD.

Ann Oncol. 2012 Dec;23(12):3180-7. doi: 10.1093/annonc/mds179. Epub 2012 Aug 2.

19.

[Gastrointestinal stromal tumors: evolution of a tumor concept from unclassifiable neoplasms to targeted molecular therapy].

Agaimy A, Schneider-Stock R.

Pathologe. 2010 Mar;31(2):115-22. doi: 10.1007/s00292-009-1247-8. Review. German.

PMID:
19949796
20.

Recent advances in therapy for gastrointestinal stromal tumors.

Maki RG.

Curr Oncol Rep. 2007 May;9(3):165-9. Review.

PMID:
17430686
Items per page

Supplemental Content

Write to the Help Desk